PO-53 Phase II study of low molecular weight heparin (LMWH) in combination with immunotherapy in metastatic renal cell carcinoma patients

Tsimafeyeu, Ilya; Маджуга, А В; Демидов, Лев В.; Сомонова, О В; Yelizarova, A.

doi:10.1016/s0049-3848(07)70206-2

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine studies were included in the meta‐analysis . We fully evaluated 28 studies that met the criterion for inclusion in our meta‐analysis, but excluded 19 of these because of unavailable data on 1‐year survival outcomes . For one of the studies, the 1‐year survival data were extracted from the Kaplan–Meier survival curves .…”

Section: Resultsmentioning

confidence: 99%

“…As in our previous study, data available from individual studies lacked uniformity, and information was missing. Nineteen of the studies that we retrieved for data extraction did not report 1‐year mortality, and we were unable to include these in our meta‐analysis . We attempted to contact the corresponding authors of these studies to obtain 1‐year mortality data, but either these were unavailable or we received no response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials

Sanford

Naidu

Alizadeh

et al. 2014

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Sanford D, Naidu A, Alizadeh N, Lazo-Langner A. The effect of low molecular weight heparin on survival in cancer patients:an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 2014; 12: 1076-85.Summary. Background: Tumors may exploit the coagulation system to enhance the survival and dissemination of cancer cells. Some studies have suggested that heparin and low molecular weight heparin (LMWH) have antitumor effects. We reported a previous meta-analysis that suggested a modest improvement in overall survival with the use of LMWH in patients with cancer. Herein, we present the results of an updated systematic review and meta-analysis. Objective: To evaluate the effect of LMWH as compared with placebo or no anticoagulant on the overall survival in patients with solid cancers. Methods: We conducted a systematic review and metaanalysis of randomized trials evaluating the use of LMWH vs. placebo or no anticoagulant in cancer patients without venous thrombosis. A meta-analysis was conducted with a random-effects model, and data were analyzed by the use of odds ratios (ORs) and relative risks (RRs) calculated for 1-year overall mortality. Results: We identified 724 potentially relevant studies, nine of which met our inclusion criteria, and reported data on 1-year overall mortality. Studies were heterogeneous regarding types of cancer and interventions, and included 5987 patients, 98.4% of whom had advancedstage disease (III and IV). There was no discernible effect on mortality with the use of LMWH (pooled OR 0.87, 95% CI 0.70-1.08; RR 0.94, 95% CI 0.86-1.04). Conclusions: In contrast to the previous study, these results did not show a survival benefit in cancer patients receiving LMWH. The effect of LMWH on overall survival in patients with limited-stage disease still is unknown.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%